Enacts provisions relating to insurance coverage for prescription insulin drugs

Summary

The bill caps patient cost‑sharing for a 30‑day supply of prescription insulin at $30 and forces health plans to calculate that amount after subtracting all rebates they receive. It also shields rebate details as trade secrets and would apply to any health benefit plan beginning Jan. 1, 2027. The measure failed to pass.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share